October 3, 2016
A new report by the European Observatory on Infringements of Intellectual Property Rights assesses the economic impact of counterfeiting and piracy in the pharma sector. The economic cost of IPR infringement in the pharmaceutical industryunderscores the serious public health threat posed by counterfeit medicines. Estimates suggest that 10% of all medicines supplied globally are falsified. The report further estimates that counterfeiting costs the pharmaceutical industry and Europe more than €10 billion each year and may result in the loss of up to 40,000 direct jobs. Taking into account the broader and indirect effects of counterfeit pharmaceuticals on other sectors, this translates to a negative impact of over €17 billion and 90,000 job losses. Welcoming the report, the European Federation of Pharmaceutical Industries and Associations (EFPIA) said: "It is only via a multi-stakeholder and multi-disciplinary, collaborative approach that we can ensure success in the fight against this negative and life-threatening phenomenon."
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.